0000-0002-6634-2893

Up a level
Export as [feed] RSS
Group by: Date | Item Type | Refereed | No Grouping
Jump to: 2020 | 2019 | 2018

2020

Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu; Zhang, Wu; Yang, Dongyun; Cremolini, Chiara; Murgioni, Sabina; Lonardi, Sara; Ning, Yan; Okazaki, Satoshi; Berger, Martin D.; Miyamoto, Yuji; Barzi, Afsaneh; Loupakis, Fotios; Falcone, Alfredo; Lenz, Heinz-Josef (2020). Single Nucleotide Polymorphisms in MiRNA Binding Sites of Nucleotide Excision Repair-Related Genes Predict Clinical Benefit of Oxaliplatin in FOLFOXIRI Plus Bevacizumab: Analysis of the TRIBE Trial. Cancers, 12(7) MDPI AG 10.3390/cancers12071742

Miyamoto, Yuji; Schirripa, Marta; Suenaga, Mitsukuni; Cao, Shu; Zhang, Wu; Okazaki, Satoshi; Berger, Martin D.; Matsusaka, Satoshi; Yang, Dongyun; Ning, Yan; Baba, Hideo; Loupakis, Fotios; Lonardi, Sara; Pietrantonio, Filippo; Borelli, Beatrice; Cremolini, Chiara; Yamaguchi, Toshiharu; Lenz, Heinz-Josef (2020). A polymorphism in the cachexia-associated gene INHBA predicts efficacy of regorafenib in patients with refractory metastatic colorectal cancer. PLoS ONE, 15(9), e0239439. Public Library of Science 10.1371/journal.pone.0239439

2019

Suenaga, Mitsukuni; Cao, Shu; Zhang, Wu; Yang, Dongyun; Ning, Yan; Okazaki, Satoshi; Berger, Martin Dave; Miyamoto, Yuji; Schirripa, Marta; Soni, Shivani; Barzi, Afsaneh; Yamaguchi, Toshiharu; Lenz, Heinz-Josef (2019). Genetic variants in CCL5 and CCR5 genes and serum VEGF-A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients. International journal of cancer, 144(10), pp. 2567-2577. Wiley-Blackwell 10.1002/ijc.31968

2018

Suenaga, Mitsukuni; Schirripa, Marta; Cao, Shu; Zhang, Wu; Yang, Dongyun; Cremolini, Chiara; Lonardi, Sara; Bergamo, Francesca; Ning, Yang; Yamamoto, Noriko; Okazaki, Satoshi; Berger, Martin Dave; Miyamoto, Yuji; Gopez, Roel; Barzi, Afsaneh; Yamaguchi, Toshiharu; Stintzing, Sebastian; Heinemann, Volker; Loupakis, Fotios; Falcone, Alfredo; ... (2018). Potential role of PIN1 genotypes in predicting benefit from oxaliplatin-based and irinotecan-based treatment in patients with metastatic colorectal cancer. The pharmacogenomics journal, 18(5), pp. 623-632. Nature Publishing Group 10.1038/s41397-018-0030-8

Provide Feedback